Wednesday, October 22, 2025

Revive Therapeutics Appoints Airway Disease Expert As Advisor For COVID-19 Phase 3 Study

Revive Therapeutics (CSE: RVV) has strengthened its scientific and advisory team as it looks to close out the year. Dr John Fahy, MD, MSc has joined the company as a scientific and clinical advisor to assist the company in the expansion and analysis of clinical data from the currently ongoing phase 3 clinical trial evaluating the safety and efficacy of Bucillamine against mild to moderate COVID-19.

A Professor of Medicine within the Division of Pulmonary and Critical Care Medicine at the Department of Medicine at The University of California San Francisco, Fahy has numerous roles within the field related to asthma, fibrosis, and other airway diseases. Such roles include the role of being the Michael S Stulbarg Endowed Chair in Pulmonary Medicine, as well as a director of UCSF Airway Clinical Research Center and UCSF’s severe asthma clinic.

Even more significantly, and perhaps more relevant to Revive Therapeutics, Fahy is the author of a study that was recently published, which is entitled, “Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry.” The relevance here is that the study shows that thiol-based drugs, such as Bucillamine, decrease the binding of spike proteins related to COVID-19 to the receptor, decreasing the efficiency of the virus and inhibiting live virus infection. The study provided rationale to test thiol-based drugs, such as Bucillamine, as treatments against COVID-19.

“Dr. Fahy is a distinguished clinical researcher with thiol-based drugs, such as Bucillamine, and his understanding of its mechanism of action and how it relates to SARS-CoV-2 will be valuable in assessing our interim analysis of our FDA Phase 3 study.”

Michael Frank, CEO of Revive Therapeutics

Revive Therapeutics last traded at $0.57 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Steadright Enters MOU To Acquire Historic Goundafa Polymetallic Mine In Morocco

Military Seizes Power in Madagascar After President Flees

Related News

Revive Selects Clinical Sites for FDA Phase 3 Clinical Trials

This morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical...

Tuesday, September 29, 2020, 09:45:22 AM

Revive Therapeutics Continues With Phase 3 Clinical Trial For Bucillamine, To File For Emergency Use Authorization

Revive Therapeutics (CSE: RVV) issued an update to the market this morning related to its...

Wednesday, December 23, 2020, 09:48:31 AM

Revive Seeks To Advance Bucillamine Study To Phase 2 Clinical Study

This morning, Revive Therapeutics (CSE: RVV) released an update in relation to its ongoing study...

Monday, March 30, 2020, 08:31:03 AM

Revive Receives Approval From Independent Review Board For Phase Three Study

Revive Therapeutics (CSE: RVV) is one step closure to commencing its phase three clinical trials...

Monday, August 31, 2020, 08:56:26 AM

Revive Therapeutics Signs MOU With Attwill Medical, Manufacturer For Vaxart, For Phase 3 Clinical Trials

Revive Therapeutics (CSE: RVV) (OTC: RVVTF) is one step closer to conducting its phase 3...

Friday, August 14, 2020, 08:50:35 AM